Madrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial

Reuters

13 May

Madrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial

Madrigal Pharmaceuticals Inc. recently presented at EASL 2025, focusing on their leadership in addressing MASH (Metabolic Associated Steatohepatitis) and showcasing new findings on Compensated MASH Cirrhosis (F4c). The presentation included an overview of F4c and clinically significant portal hypertension, alongside a review of new two-year open-label data from the Phase 3 MAESTRO-NAFLD-1 trial. Through these insights, Madrigal aims to reinforce confidence in MAESTRO-NASH outcomes. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2535282727"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535282727\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535282727?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535282727","market":"us","top_or_hot":-1,"title":"Madrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Madrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Madrigal Pharmaceuticals Inc. recently presented at EASL 2025, focusing on their leadership in addressing MASH (Metabolic Associated Steatohepatitis) and showcasing new findings on Compensated MASH Cirrhosis (F4c). The presentation included an overview of F4c and clinically significant portal hypertension, alongside a review of new two-year open-label data from the Phase 3 MAESTRO-NAFLD-1 trial. Through these insights, Madrigal aims to reinforce confidence in MAESTRO-NASH outcomes. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Madrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMadrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-13 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Madrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Madrigal Pharmaceuticals Inc. recently presented at EASL 2025, focusing on their leadership in addressing MASH (Metabolic Associated Steatohepatitis) and showcasing new findings on Compensated MASH Cirrhosis (F4c). The presentation included an overview of F4c and clinically significant portal hypertension, alongside a review of new two-year open-label data from the Phase 3 MAESTRO-NAFLD-1 trial. Through these insights, Madrigal aims to reinforce confidence in MAESTRO-NASH outcomes. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL8lYwjm:1","article_id":"2535282727","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535282727","pubTimestamp":1747137958,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Madrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial. Madrigal Pharmaceuticals Inc. recently presented at EASL 2025, focusing on their leadership in addressing MASH  and showcasing new findings on Compensated MASH Cirrhosis . The presentation included an overview of F4c and clinically significant portal hypertension, alongside a review of new two-year open-label data from the Phase 3 MAESTRO-NAFLD-1 trial. Through these insights, Madrigal aims to reinforce confidence in MAESTRO-NASH outcomes. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc.","BK4139":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Madrigal Pharmaceuticals Inc.发布关于代偿性MASH肝硬化和REZDIFFRA 3期MAESTRO-NAFLD-1试验数据的演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":0.9},"content_text":"Madrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial\n    \n\n        Madrigal Pharmaceuticals Inc. recently presented at EASL 2025, focusing on their leadership in addressing MASH (Metabolic Associated Steatohepatitis) and showcasing new findings on Compensated MASH Cirrhosis (F4c). The presentation included an overview of F4c and clinically significant portal hypertension, alongside a review of new two-year open-label data from the Phase 3 MAESTRO-NAFLD-1 trial. Through these insights, Madrigal aims to reinforce confidence in MAESTRO-NASH outcomes. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}